Matritech's NMP22(R) BladderChek(R) Test will be Featured in Presentations at the American Urological Association (AUA) Annual M
14 Mai 2007 - 3:02PM
Business Wire
Matritech (Amex: MZT), a leading developer and marketer of
protein-based diagnostic products for the early detection of
cancer, announced today that the NMP22� BladderChek� Test will be
included in a plenary session State-of-the-Art lecture and two
discussed poster presentations May 21-22, 2007 at the American
Urological Association (AUA) annual meeting in Anaheim, California.
More than 10,000 urologists and healthcare professionals are
expected to attend the conference. This year�s presentations
support using the NMP22 BladderChek Test as a critical tool for
regularly evaluating patients at high risk for bladder cancer:
long-time smokers, people who work around particles in
manufacturing, or who work with chemicals like those in hair dyes,
or toxic fumes like firefighters. During the past year, the Test
has been increasingly used in screening programs for firefighters,
most recently by the city of San Francisco, and by occupational
health groups to test people in high-risk occupations for bladder
cancer. Highlights of the AUA accepted abstracts on the NMP22
BladderChek Test and scheduled presentation are as follows: Monday,
May 21, 2007 3:30 � 5:30 PM Moderated Poster Sessions � Bladder
Cancer Detection and Screening Poster #1083 �Impact of Risk Factors
on the Performance of a Point-of-Care Bladder Cancer Test,� Yair
Lotan, M.D., University of Texas, Southwestern Medical Center In
this study at risk patient groups are segmented and analyzed to
demonstrate the positive predictive value of the NMP22 BladderChek
Test for detecting bladder cancer. Dr. Lotan has previously
reported on and published results from his analyses which
demonstrated that screening for bladder cancer can save money as
well as lives, by finding more cancers before they become muscle
invasive. If testing is focused on patients at high risk and
conducted with the low cost NMP22� BladderChek� Test the money
saved in treatment expense is greater than the cost of screening.
Poster #1098 �NMP22 as an Adjunct to Urine Cytology and Cystoscopy
in Follow-up of Superficial TCC of the Urinary Bladder,� Narmada P.
Gupta, M.D., New Delhi, India In this study of patients with
bladder cancer, a positive NMP22 BladderChek Test result during
initial treatment was associated with a significantly greater risk
of tumor recurrence within one year of follow up. Tuesday, May 22,
2007 11:10 AM � Plenary Session State-of-the-Art Lecture: �Is
Screening for Bladder Cancer Ready for Prime Time?� H. Barton
Grossman, M.D., Deputy Chairman, Department of Urology, M.D.
Anderson Cancer Center, Houston, TX Dr. Grossman is the lead author
and principal investigator of the two studies published in JAMA on
the NMP22 BladderChek Test. In previous presentations on the use of
tumor markers in the diagnosis of bladder cancer, he has pointed
out that the NMP22 BladderChek Test was proven to identify cancers
missed by cystoscopy in two large clinical trials, citing the
publications in JAMA. He has also emphasized that when using any
diagnostic test it is important to understand its performance
characteristics. Dr. Grossman has drawn attention to the
significantly better negative predictive value (NPV), or
reliability of a negative test result, of the point-of-care NMP22
BladderChek Test, which has fewer missed cancers (false negatives),
compared to the urine cytology laboratory based test. In addition
to the presentations on the NMP22 BladderChek Test, Dr. Mark S.
Soloway Chairman, Department of Urology, University of Miami
Leonard M. Miller School of Medicine, a clinical investigator and
co-author of two studies published in the Journal of the American
Medical Association (JAMA) on the NMP22 BladderChek Test will be
hosting a Lunch with the Expert. He is considered an international
leader on bladder cancer detection, research and treatment. He is a
vocal advocate for improving the early detection of this disease,
authoring papers calling for better education of the public and
primary care physicians. �With urine-based markers that are now on
the scene and with public information and targeting those cigarette
smokers that are at risk, older individuals, and anyone with blood
in the urine, I believe we now have an opportunity to make a major
change for the earlier diagnosis of men and women with bladder
cancer,� he has been quoted as saying. Screening, especially in
high-risk populations is an area of research for Dr. Soloway. He is
a co-author of poster #1082 with Dr. Alan Neider, et al., entitled
"Evaluation and Work-up of Hematuria among Primary Care Physicians
in Miami-Dade County: An Anonymous Questionnaire-based Survey." In
this survey, only 36% and 77% of patients with microscopic and
gross hematuria are referred to urology. The authors conclude that
screening for microscopic hematuria may be appropriate since these
patients are not automatically referred to urology and may
encounter a delay in diagnosis ... [and] Further prospective
studies are warranted to evaluate the efficacy of screening for UC,
especially in high-risk populations. Information about the NMP22
BladderChek Test will be available at Matritech�s booth #516. About
the NMP22� BladderChek� Test The NMP22� BladderChek� Test was
developed and commercialized by Matritech, a leading developer and
marketer of protein-based diagnostic products for the early
detection of cancer. The NMP22 BladderChek Test detects elevated
levels of the NMP22 protein marker in a single urine sample. Most
healthy individuals have very small amounts of the NMP22 protein
marker in their urine, but bladder cancer patients commonly have
elevated NMP22 marker levels, even at early stages of the disease.
The NMP22 BladderChek Test, a painless and noninvasive assay, is
the only in-office test approved by the FDA for both the diagnosis
and monitoring of bladder cancer. It is used in a physician�s
office, requires only four drops of urine and results are available
in 30 minutes � during the patient visit, allowing a rapid and
accurate way to aid in the detection of bladder cancer. The NMP22
BladderChek Test is reimbursed by Medicare and many medical
insurers and has an average cost of less than $30. It also has been
shown to detect over three times as many cancers as the commonly
used laboratory based urine cytology test. Two studies published in
the Journal of the American Medical Association (JAMA) in February
2005 and January 2006 reported on clinical data showing the NMP22
BladderChek Test used in combination with cystoscopy for the
diagnosis and monitoring of bladder cancer detected up to 99% of
bladder malignancies. The NMP22� BladderChek� Test also detected
cancers that were missed during an initial cystoscopic examination,
most of which were high grade. In other clinical study analyses it
was shown to detect 100% of the aggressive tumors, one of which was
muscle invasive, in women with symptoms or risk factors for bladder
cancer. It was also reported to detect all the transitional cell
cancers that occurred in the upper urinary tract of patients with
risk factors or symptoms of bladder cancer. Cystoscopy did not
identify these tumors because they were outside the viewing area of
the instrument. The San Francisco Fire Department is using the
NMP22 BladderChek Test in an annual screening program of active and
retired firefighters for bladder cancer. In addition to San
Francisco, voluntary screening of firefighters with the NMP22
BladderChek Test is on-going or has occurred in a number of smaller
communities throughout the country. Legislation providing for the
screening of firefighters is being considered in Rhode Island,
Florida, New York, Vermont and Massachusetts. The NMP22 BladderChek
Test is also being used by local wellness and/or occupational
health programs to test individuals in Arizona, Colorado,
Wisconsin, Texas, Michigan, Kentucky, New York, Massachusetts,
Washington, DC and Rhode Island. About Matritech Matritech is using
its patented proteomics technology to develop diagnostics for the
detection of a variety of cancers. The Company's first two
products, the NMP22� Test Kit and NMP22� BladderChek� Test, have
been FDA approved for the monitoring and diagnosis of bladder
cancer. The NMP22 BladderChek Test is based on Matritech's
proprietary nuclear matrix protein (NMP) technology, which
correlates levels of NMPs in body fluids to the presence of cancer.
Beginning with a patent portfolio licensed exclusively from the
Massachusetts Institute of Technology (MIT), Matritech�s patent
portfolio has grown to 14 other U.S. patents. In addition to the
NMP22 protein marker utilized in the NMP22 Test Kit and NMP22
BladderChek Test, the Company has discovered other proteins
associated with cervical, breast, prostate, and colon cancer. The
Company�s goal is to utilize protein markers to develop, through
its own research staff and through strategic alliances, clinical
applications to detect cancer. More information about Matritech is
available at www.matritech.com. Statement under the Private
Securities Litigation Reform Act Any forward-looking statements
relate to the Company's current expectations of the Company�s NMP22
products and technology. Actual results may differ materially from
those predicted in such forward-looking statements due to the risks
and uncertainties inherent in the Company�s business, including
without limitation risks and uncertainties including those detailed
in the Company's periodic reports and registration statements as
filed with the Securities and Exchange Commission. These
forward-looking statements are neither promises nor guarantees.
There can be no assurance that the Company's expectations for its
products will be achieved. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Matritech undertakes no responsibility to
revise or update any such forward-looking information.
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024